vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and Orchid Island Capital, Inc. (ORC). Click either name above to swap in a different company.

Orchid Island Capital, Inc. is the larger business by last-quarter revenue ($38.5M vs $20.6M, roughly 1.9× Pulmonx Corp). Orchid Island Capital, Inc. runs the higher net margin — 268.7% vs -66.3%, a 335.0% gap on every dollar of revenue. On growth, Orchid Island Capital, Inc. posted the faster year-over-year revenue change (372.6% vs -8.7%). Over the past eight quarters, Orchid Island Capital, Inc.'s revenue compounded faster (301.6% CAGR vs -0.5%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.

LUNG vs ORC — Head-to-Head

Bigger by revenue
ORC
ORC
1.9× larger
ORC
$38.5M
$20.6M
LUNG
Growing faster (revenue YoY)
ORC
ORC
+381.3% gap
ORC
372.6%
-8.7%
LUNG
Higher net margin
ORC
ORC
335.0% more per $
ORC
268.7%
-66.3%
LUNG
Faster 2-yr revenue CAGR
ORC
ORC
Annualised
ORC
301.6%
-0.5%
LUNG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
ORC
ORC
Revenue
$20.6M
$38.5M
Net Profit
$-13.7M
$103.4M
Gross Margin
77.9%
Operating Margin
-40.9%
Net Margin
-66.3%
268.7%
Revenue YoY
-8.7%
372.6%
Net Profit YoY
5.5%
1764.9%
EPS (diluted)
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
ORC
ORC
Q1 26
$20.6M
Q4 25
$22.6M
$38.5M
Q3 25
$21.5M
$26.9M
Q2 25
$23.9M
$23.2M
Q1 25
$22.5M
$19.7M
Q4 24
$23.8M
Q3 24
$20.4M
$340.0K
Q2 24
$20.8M
$-697.0K
Net Profit
LUNG
LUNG
ORC
ORC
Q1 26
$-13.7M
Q4 25
$-10.4M
$103.4M
Q3 25
$-14.0M
$72.1M
Q2 25
$-15.2M
$-33.6M
Q1 25
$-14.4M
$17.1M
Q4 24
$-13.2M
Q3 24
$-14.1M
$17.3M
Q2 24
$-15.3M
$-5.0M
Gross Margin
LUNG
LUNG
ORC
ORC
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
LUNG
LUNG
ORC
ORC
Q1 26
-40.9%
Q4 25
-43.8%
Q3 25
-66.9%
Q2 25
-62.0%
Q1 25
-64.6%
Q4 24
-56.5%
Q3 24
-69.3%
Q2 24
-75.2%
Net Margin
LUNG
LUNG
ORC
ORC
Q1 26
-66.3%
Q4 25
-46.1%
268.7%
Q3 25
-64.9%
267.8%
Q2 25
-63.6%
-145.0%
Q1 25
-64.1%
86.9%
Q4 24
-55.4%
Q3 24
-69.4%
5094.1%
Q2 24
-73.7%
714.3%
EPS (diluted)
LUNG
LUNG
ORC
ORC
Q1 26
$-0.33
Q4 25
$-0.25
Q3 25
$-0.34
Q2 25
$-0.38
Q1 25
$-0.36
Q4 24
$-0.33
Q3 24
$-0.36
Q2 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
ORC
ORC
Cash + ST InvestmentsLiquidity on hand
$61.6M
$665.9M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$45.8M
$1.4B
Total Assets
$120.0M
$11.7B
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
ORC
ORC
Q1 26
$61.6M
Q4 25
$69.8M
$665.9M
Q3 25
$76.5M
$583.9M
Q2 25
$75.5M
$440.8M
Q1 25
$74.6M
$396.4M
Q4 24
$70.9M
Q3 24
$63.3M
$322.1M
Q2 24
$63.5M
$241.0M
Total Debt
LUNG
LUNG
ORC
ORC
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
LUNG
LUNG
ORC
ORC
Q1 26
$45.8M
Q4 25
$54.1M
$1.4B
Q3 25
$60.0M
$1.1B
Q2 25
$69.1M
$912.0M
Q1 25
$77.7M
$855.9M
Q4 24
$85.8M
Q3 24
$93.9M
$656.0M
Q2 24
$101.2M
$555.9M
Total Assets
LUNG
LUNG
ORC
ORC
Q1 26
$120.0M
Q4 25
$129.3M
$11.7B
Q3 25
$138.3M
$9.1B
Q2 25
$147.2M
$7.6B
Q1 25
$150.7M
$7.3B
Q4 24
$162.8M
Q3 24
$167.4M
$5.9B
Q2 24
$172.6M
$4.9B
Debt / Equity
LUNG
LUNG
ORC
ORC
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
ORC
ORC
Operating Cash FlowLast quarter
$120.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.16×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
ORC
ORC
Q1 26
Q4 25
$-7.1M
$120.4M
Q3 25
$-8.2M
$28.0M
Q2 25
$-3.9M
$18.4M
Q1 25
$-13.2M
$25.8M
Q4 24
$-6.7M
Q3 24
$-7.2M
$-14.8M
Q2 24
$-5.8M
$19.3M
Free Cash Flow
LUNG
LUNG
ORC
ORC
Q1 26
Q4 25
$-7.1M
Q3 25
$-8.3M
Q2 25
$-4.0M
Q1 25
$-13.5M
Q4 24
$-6.8M
Q3 24
$-7.7M
Q2 24
$-6.2M
FCF Margin
LUNG
LUNG
ORC
ORC
Q1 26
Q4 25
-31.4%
Q3 25
-38.4%
Q2 25
-16.6%
Q1 25
-60.0%
Q4 24
-28.8%
Q3 24
-37.6%
Q2 24
-30.0%
Capex Intensity
LUNG
LUNG
ORC
ORC
Q1 26
Q4 25
0.1%
Q3 25
0.4%
Q2 25
0.2%
Q1 25
1.3%
Q4 24
0.5%
Q3 24
2.0%
Q2 24
2.3%
Cash Conversion
LUNG
LUNG
ORC
ORC
Q1 26
Q4 25
1.16×
Q3 25
0.39×
Q2 25
Q1 25
1.51×
Q4 24
Q3 24
-0.86×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons